Efzofitimod, A Novel Immunomodulator for Pulmonary Sarcoidosis, modulates Patient Inflammatory Responses Through Myeloid Cells

Pulmonary sarcoidosis is a complex immune disease characterized by the recruitment and accumulation of





¹Broos, EB, et al. Granuloma formation in pulmonary sarcoidosis. *Frontiers in Immunology*. 4,437 (2013)

²Baughman, RP, et al. Efzofitimod: A novel anti-inflammatory agent for sarcoidosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 40,1 (2023) ³Adams, R, et al. Efzofitimod (ATYR1923) treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients. American Thoracic Society, P560 (2023) ⁴Foerster, et. Al. Manuscript under review

D. Siefker¹, Z. Xu¹, S. Paz¹, M. Ferrer¹, E. Escobedo¹, Y. Chong¹, L. Burman¹, L. Zhai², L. Eide¹, C. Polizzi¹, C. Burkart¹, G. Walker¹, R. Adams¹, L. Nangle¹ ¹aTyr Pharma - San Diego (USA), ²Pangu/HKUST- Hong Kong (China)